Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

  • Doug Jones and the ACA, Epic misses a White House meeting, and man caves for man-flu sufferers
  • CVS-Aetna deal may trigger merger mania, Johns Hopkins criticized for lack of asthma prevention, & Columbia sees free-ride future for all of its med students

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.

News

The FDA has approved olaparib (Lynparza, AstraZeneca/Merck) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant,…
The shortage of small-volume parenteral solutions often supplied in intravenous fluid bags is affecting virtually all U.S. hospitals, according to results of a survey by the American Society of Health-System Pharmacists (ASHP). Nearly all of the respondents (99.1%) to the informal, nonscientific survey…
The Trump administration will allow states to test requiring some Medicaid recipients to work or participate in community activities such as volunteering or jobs training as a condition of eligibility for the government health insurance program for the poor. The Centers for Medicare and Medicaid Services…
Women with moderate to severe iodine deficiency may take longer to achieve a pregnancy compared to women with normal iodine levels, according to a study by researchers at the National Institutes of Health. The study is the first to investigate the potential effects of mild to moderate iodine deficiency—common…
New expert guidance released by the Society for Healthcare Epidemiology of America offers advice to hospitals on determining when they can safely discontinue contact precautions for patients with multi-drug resistant bacteria. The framework, published in Infection Control and Hospital Epidemiology,…
An FDA advisory committee has declined to recommend approval of a proposed new oral testosterone replacement therapy (Tlando, Lipocine Inc.). Lipocine said the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) voted six in favor and 13 against the benefit–risk profile of Tlando, which…
The FDA has granted a breakthrough therapy designation for Eisai’s multiple receptor tyrosine kinase inhibitor lenvatinib mesylate (Lenvima) in combination with Merck’s anti-programmed death-1 therapy pembrolizumab (Keytruda) for the potential treatment of patients with advanced and/or metastatic…
In the last few decades, dozens of new breast cancer drugs—from chemotherapies to targeted compounds—have become available for clinical use, and mammogram technology has gone from film to digital. But are the changes making a difference in how many women die of breast cancer? The answer to that…